Cervical Cancer

Cadonilimab potentially offers better PFS than pembrolizumab and atezolizumab therapies in recurrent advanced metastatic cervical cancer

Second- or third-line treatment with tisotumab vedotin significantly improves overall survival and progression-free survival compared to chemotherapy in patients with recurrent cervical cancer.

Tisotumab vedotin showed clinically meaningful and durable antitumor activity with a manageable and tolerable safety profile in women with previously treated recurrent or metastatic cervical cancer.

The addition of bevacizumab to combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer improved median overall survival by 3.7 months and was associated with higher response rates.

Cisplatin-based concomitant chemoradiation resulted in superior DFS compared to neoadjuvant chemotherapy followed by radical surgery in patients with locally advanced cervical cancer.